News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website


High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

We already knew that there is a high frequency of this mutation in the pediatric thalamic tumors but this study shows that 60% of adult thalamic tumors have this mutation.    Glioblastoma in this area have the worst prognosis. This article shows why - all are MGMT unmethylated, and most have the H3K27M mutation.    The good news about all of this is that now we have options that we did not have before:

 For the H3K27M mutation, the experimental drug Onc-201 can be tried. There are trials available for it and if you do not fit the trial, we are involved in a compassionate use program for it - call us.  

 For the unmethylated MGMT, there is a different experimental drug - Val-083 which is in trial that is similar to Temodar but works in a different area of the DNA so it is unaffected by the MGMT status.

 


Posted on: 04/03/2019

High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740